BusinessOcera to Present at the Cowen and Company 37th Annual Healthcare ConferenceBy Nasdaq OMXFeb 28, 2017, 9:05 PM UTC
BusinessOcera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with CirrhosisBy Nasdaq OMXJan 5, 2017, 2:05 PM UTC
BusinessOcera Completes Enrollment of STOP-HE, a Phase 2b Study of OCR-002 in Hospitalized Patients with Hepatic EncephalopathyBy Nasdaq OMXDec 7, 2016, 2:05 PM UTC
BusinessOcera to Present at the Stifel 2016 Healthcare ConferenceBy Nasdaq OMXNov 9, 2016, 2:05 PM UTC
BusinessOcera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016By Nasdaq OMXOct 24, 2016, 1:05 PM UTC
BusinessOcera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver FailureBy Nasdaq OMXSep 21, 2016, 8:05 PM UTC
BusinessOcera to Present at the Ladenburg Thalmann 2nd Annual Healthcare ConferenceBy Nasdaq OMXSep 20, 2016, 1:10 PM UTC
BusinessOcera Initiates Phase 1 Clinical Study of Orally Available OCR-002 in Patients with Cirrhosis for the Prevention of Hepatic EncephalopathyBy Nasdaq OMXSep 19, 2016, 1:05 PM UTC
